Survival after neuroAIDS: Association with antiretroviral CNS Penetration-Effectiveness score

Neurology

Volumn 76, Issue 7, 2011, Pages 644-651

  Lanoy, E ^a,b   Guiguet, M ^a,b   Bentata, M ^c   Rouveix, E ^d   Dhiver, C ^e   Poizot Martin, I ^f   Costagliola, D ^a,b,g   Gasnault, J ^h  

^a NSERM   (France)

^b SORBONNE UNIVERSITÉ   (France)

^c AVICENNE HOSPITAL   (France)

^d HÔPITAL AMBROISE PARÉ   (France)

^e HÔPITAL DE LA CONCEPTION   (France)

^f HÔPITAL SAINTE MARGUERITE   (France)

^g ASSISTANCE PUBLIQUE HÔPITAUX DE PARIS   (France)

^h BICÊTRE HOSPITAL   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRETROVIRUS AGENT; VIRUS RNA;

ADULT; ARTICLE; BRAIN DISEASE; CNS PENETRATION EFFECTIVENESS SCORE; COGNITION; CONTROLLED STUDY; CRYPTOCOCCAL MENINGITIS; FEMALE; FOLLOW UP; HIV RELATED ENCEPHALOPATHY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; MAJOR CLINICAL STUDY; MALE; MORTALITY; PRIORITY JOURNAL; PROGRESSIVE MULTIFOCAL LEUKOENCEPHALOPATHY; PROSPECTIVE STUDY; SCORING SYSTEM; SURVIVAL; TOXOPLASMOSIS; VIRUS LOAD;

EID: 79951644974     PISSN: 00283878     EISSN: 1526632X     Source Type: Journal    
DOI: 10.1212/WNL.0b013e31820c3089     Document Type: Article

References (23)

1. Bhaskaran K, Mussini C, Antinori A, et al. Changes in the incidence and predictors of human immunodeficiency virus-associated dementia in the era of highly active antiret-roviral therapy. Ann Neurol 2008;63:213-221. (Pubitemid 351355300)
2. D'Arminio Monforte A, Cinque P, Mocroft A, et al. Changing incidence of central nervous system diseases in the EuroSIDA cohort. Ann Neurol 2004;55:320-328. (Pubitemid 38292033)
3. Sacktor N, Tarwater PM, Skolasky RL, et al. CSF antiretrovi-ral drug penetrance and the treatment of HIV-associated psy-chomotor slowing. Neurology 2001;57:542-544. (Pubitemid 32757613)
4. Sevigny JJ, Albert SM, McDermott MP, et al. Evaluation of HIV RNA and markers of immune activation as predictors of HIV-associated dementia. Neurology 2004;63: 2084-2090. (Pubitemid 39636256)
5. Sacktor N, McDermott MP, Marder K, et al. HIV-associated cognitive impairment before and after the advent of combination therapy. J Neurovirol 2002;8:136-142. (Pubitemid 34520894)
6. Dore GJ, McDonald A, Li Y, Kaldor JM, Brew BJ. Marked improvement in survival following AIDS dementia complex in the era of highly active antiretroviral therapy. AIDS 2003;17:1539-1545. (Pubitemid 36900555)
7. Mocroft A, Sterne JA, Egger M, et al. Variable impact on mortality of AIDS-defining events diagnosed during combination antiretroviral therapy: not all AIDS-defining conditions are created equal. Clin Infect Dis 2009;48:1138-1151.
8. Grabar S, Lanoy E, Allavena C, et al. Causes of the first AIDS-defining illness and subsequent survival before and after the advent of combined antiretroviral therapy. HIV Med 2008;9:246-256. (Pubitemid 351467799)
9. Solas C, Lafeuillade A, Halfon P, Chadapaud S, Hittinger G, Lacarelle B. Discrepancies between protease inhibitor concentrations and viral load in reservoirs and sanctuary sites in human immunodeficiency virus-infected patients. Antimicrob Agents Chemother 2003;47:238-243. (Pubitemid 36070370)
10. Coombs RW, Speck CE, Hughes JP, et al. Association between culturable human immunodeficiency virus type 1 (HIV-1) in semen and HIV-1 RNA levels in semen and blood: evidence for compartmentalization of HIV-1 between semen and blood. J Infect Dis 1998;177:320-330. (Pubitemid 28063755)
11. Strazielle N, Ghersi-Egea JF. Factors affecting delivery of antiviral drugs to the brain. Rev Med Virol 2005;15:105-133. (Pubitemid 40343194)
12. Clements JE, Li M, Gama L, et al. The central nervous system is a viral reservoir in simian immunodeficiency virus-infected macaques on combined antiretroviral therapy: a model for human immunodeficiency virus patients on highly active antiretroviral therapy. J Neurovirol 2005; 11:180-189. (Pubitemid 40852425)
13. Letendre S, Marquie-Beck J, Capparelli E, et al. Validation of the CNS Penetration-Effectiveness rank for quantifying antiretroviral penetration into the central nervous system. Arch Neurol 2008;65:65-70.
14. Marra CM, Zhao Y, Clifford DB, et al. Impact of combination antiretroviral therapy on cerebrospinal fluid HIV RNA and neurocognitive performance. AIDS 2009;23: 1359-1366.
15. Tassie JM, Gasnault J, Bentata M, et al. Survival improvement of AIDS-related progressive multifocal leukoenceph-alopathy in the era of protease inhibitors: Clinical Epidemiology Group French Hospital Database on HIV. AIDS 1999;13:1881-1887. (Pubitemid 29509547)
16. Letendre S. New approaches to diagnosis and management of neurological complications in the HAART era. In: 4th International AIDS Society Conference on HIV Pathogenesis, Treatment and Prevention; Sydney; July 22-25, 2007.
17. Grabar S, Abraham B, Mahamat A, Del Giudice P, Rosenthal E, Costagliola D. Differential impact of combination antiretroviral therapy in preventing Kaposi's sarcoma with and without visceral involvement. J Clin Oncol 2006;24:3408-3414. (Pubitemid 46638897)
18. Lanoy E, Lewden C, Lievre L, et al. How does loss to follow-up influence cohort findings on HIV infection? A joint analysis of the French hospital database on HIV, Mortalite 2000 survey and death certificates. HIV Med 2009;10:236-245.
19. Lohse N, Hansen AB, Pedersen G, et al. Survival of persons with and without HIV infection in Denmark, 1995- 2005. Ann Intern Med 2007;146:87-95. (Pubitemid 351640011)
20. Cinque P, Koralnik IJ, Gerevini S, Miro JM, Price RW. Progressive multifocal leukoencephalopathy in HIV-1 infection. Lancet Infect Dis 2009;9:625-636.
21. Berger JR, Chauhan A, Galey D, Nath A. Epidemiological evidence and molecular basis of interactions between HIV and JC virus. J Neurovirol 2001;7:329-338. (Pubitemid 32894237)
22. Clifford DB, Yiannoutsos C, Glicksman M, et al. HAART improves prognosis in HIV-associated progressive multifo-cal leukoencephalopathy. Neurology 1999;52:623-625. (Pubitemid 29075615)
23. Gasnault J, Hendel Chavez H, Dorofeev E, et al. Acceleration of immune recovery on intensified ART improves survival in patients with AIDS-related progressive multifocal leukoencephalopathy: preliminary reports of the ANRS 125 Trial. In: 14th Conference of Retroviruses and Opportunistic Infections/CROI; Los Angeles; 2007.